CDS2018:孙子林:基于同伴支持和移动医疗的院外糖尿病管理模式

2018-12-02 国际糖尿病编辑部 国际糖尿病

2018年11月29日,在中华医学会糖尿病学分会第二十二次全国学术会议(CDS2018)的糖尿病健康管理专题中,东南大学附属中大医院孙子林教授就基于同伴支持和移动医疗的院外糖尿病管理模式发表了学术报告。

2018年11月29日,在中华医学会糖尿病学分会第二十二次全国学术会议(CDS2018)的糖尿病健康管理专题中,东南大学附属中大医院孙子林教授就基于同伴支持和移动医疗的院外糖尿病管理模式发表了学术报告。

根据《2型糖尿病患者健康管理服务规范》要求,我国所有确诊2型糖尿病(T2DM)的患者均要接受基层医疗卫生机构提供的综合干预,内容涉及建立健康档案、规范药物治疗、定期开展健康讲座、健康体检及评估、生活方式的指导等。但是,现有的医疗资源和模式难以满足糖尿病防控需求,如何提高干预效力以进一步提升干预效果成为糖尿病干预研究的关键点和难点。

近年来,基于同伴支持和运动医疗的院外糖尿病管理模式在糖尿病干预中展示出良好的应用前景,在提高患者依从性、节省资源方面独具特色。但是,其管理现状和作用效果如何,尚存哪些问题,均需得到答案。因此,如何建立更有效的院外健康管理模式亟待探索。

他们以医院及社区卫生服务中心糖尿病管理的患者为研究对象,探索适合中国国情的糖尿病教育新模式。通过定性研究和实验研究,探索多元化的院外社区人群糖尿病行为干预依从性的方法。

由中国微循环学会牵头的胰友支持项目,招募具有一定糖尿病知识和同伴支持意愿的糖尿病患者,进行培训考核后成为同伴组长。借助胰友支持智能平台,由医生、护士、同伴组长共同组织并管理其他患者。

目前已有452家医院参与,包含534个团队、552个小组、1258名同伴组长,共计30 496例患者,超过50%的招募患者记录了1次HbA1c水平,其中近4000人可做到每3个月检测一次HbA1c,超过70%的招募患者可做到每个月监测并记录3次以上血糖数据。通过教育管理小组成员跟进和采用智能平台新模式,患者血糖监测频率高于目前其他院外糖尿病管理模式的平均水平,空腹血糖、餐后血糖和HbA1c均有明显改善。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1931705, encodeId=96371931e055a, content=<a href='/topic/show?id=1a76e6753b9' target=_blank style='color:#2F92EE;'>#糖尿病管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76753, encryptionId=1a76e6753b9, topicName=糖尿病管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7ca4300, createdName=wodejia-dayu, createdTime=Thu Apr 04 06:42:00 CST 2019, time=2019-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377627, encodeId=dd9a13e7627c1, content=<a href='/topic/show?id=5dfe4420fc' target=_blank style='color:#2F92EE;'>#CDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4420, encryptionId=5dfe4420fc, topicName=CDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec25412, createdName=yangpeizhi, createdTime=Tue Dec 04 01:42:00 CST 2018, time=2018-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530486, encodeId=7c031530486ca, content=<a href='/topic/show?id=8309e5153aa' target=_blank style='color:#2F92EE;'>#移动医疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75153, encryptionId=8309e5153aa, topicName=移动医疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fbd812108434, createdName=yahu, createdTime=Tue Dec 04 01:42:00 CST 2018, time=2018-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1625326, encodeId=cb291625326fc, content=<a href='/topic/show?id=604fe6046b2' target=_blank style='color:#2F92EE;'>#管理模式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76046, encryptionId=604fe6046b2, topicName=管理模式)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8adf20737369, createdName=zhangj7115, createdTime=Tue Dec 04 01:42:00 CST 2018, time=2018-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042081, encodeId=d4cb104208187, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Dec 02 13:42:00 CST 2018, time=2018-12-02, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1931705, encodeId=96371931e055a, content=<a href='/topic/show?id=1a76e6753b9' target=_blank style='color:#2F92EE;'>#糖尿病管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76753, encryptionId=1a76e6753b9, topicName=糖尿病管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7ca4300, createdName=wodejia-dayu, createdTime=Thu Apr 04 06:42:00 CST 2019, time=2019-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377627, encodeId=dd9a13e7627c1, content=<a href='/topic/show?id=5dfe4420fc' target=_blank style='color:#2F92EE;'>#CDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4420, encryptionId=5dfe4420fc, topicName=CDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec25412, createdName=yangpeizhi, createdTime=Tue Dec 04 01:42:00 CST 2018, time=2018-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530486, encodeId=7c031530486ca, content=<a href='/topic/show?id=8309e5153aa' target=_blank style='color:#2F92EE;'>#移动医疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75153, encryptionId=8309e5153aa, topicName=移动医疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fbd812108434, createdName=yahu, createdTime=Tue Dec 04 01:42:00 CST 2018, time=2018-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1625326, encodeId=cb291625326fc, content=<a href='/topic/show?id=604fe6046b2' target=_blank style='color:#2F92EE;'>#管理模式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76046, encryptionId=604fe6046b2, topicName=管理模式)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8adf20737369, createdName=zhangj7115, createdTime=Tue Dec 04 01:42:00 CST 2018, time=2018-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042081, encodeId=d4cb104208187, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Dec 02 13:42:00 CST 2018, time=2018-12-02, status=1, ipAttribution=)]
    2018-12-04 yangpeizhi
  3. [GetPortalCommentsPageByObjectIdResponse(id=1931705, encodeId=96371931e055a, content=<a href='/topic/show?id=1a76e6753b9' target=_blank style='color:#2F92EE;'>#糖尿病管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76753, encryptionId=1a76e6753b9, topicName=糖尿病管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7ca4300, createdName=wodejia-dayu, createdTime=Thu Apr 04 06:42:00 CST 2019, time=2019-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377627, encodeId=dd9a13e7627c1, content=<a href='/topic/show?id=5dfe4420fc' target=_blank style='color:#2F92EE;'>#CDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4420, encryptionId=5dfe4420fc, topicName=CDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec25412, createdName=yangpeizhi, createdTime=Tue Dec 04 01:42:00 CST 2018, time=2018-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530486, encodeId=7c031530486ca, content=<a href='/topic/show?id=8309e5153aa' target=_blank style='color:#2F92EE;'>#移动医疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75153, encryptionId=8309e5153aa, topicName=移动医疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fbd812108434, createdName=yahu, createdTime=Tue Dec 04 01:42:00 CST 2018, time=2018-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1625326, encodeId=cb291625326fc, content=<a href='/topic/show?id=604fe6046b2' target=_blank style='color:#2F92EE;'>#管理模式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76046, encryptionId=604fe6046b2, topicName=管理模式)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8adf20737369, createdName=zhangj7115, createdTime=Tue Dec 04 01:42:00 CST 2018, time=2018-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042081, encodeId=d4cb104208187, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Dec 02 13:42:00 CST 2018, time=2018-12-02, status=1, ipAttribution=)]
    2018-12-04 yahu
  4. [GetPortalCommentsPageByObjectIdResponse(id=1931705, encodeId=96371931e055a, content=<a href='/topic/show?id=1a76e6753b9' target=_blank style='color:#2F92EE;'>#糖尿病管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76753, encryptionId=1a76e6753b9, topicName=糖尿病管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7ca4300, createdName=wodejia-dayu, createdTime=Thu Apr 04 06:42:00 CST 2019, time=2019-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377627, encodeId=dd9a13e7627c1, content=<a href='/topic/show?id=5dfe4420fc' target=_blank style='color:#2F92EE;'>#CDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4420, encryptionId=5dfe4420fc, topicName=CDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec25412, createdName=yangpeizhi, createdTime=Tue Dec 04 01:42:00 CST 2018, time=2018-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530486, encodeId=7c031530486ca, content=<a href='/topic/show?id=8309e5153aa' target=_blank style='color:#2F92EE;'>#移动医疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75153, encryptionId=8309e5153aa, topicName=移动医疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fbd812108434, createdName=yahu, createdTime=Tue Dec 04 01:42:00 CST 2018, time=2018-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1625326, encodeId=cb291625326fc, content=<a href='/topic/show?id=604fe6046b2' target=_blank style='color:#2F92EE;'>#管理模式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76046, encryptionId=604fe6046b2, topicName=管理模式)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8adf20737369, createdName=zhangj7115, createdTime=Tue Dec 04 01:42:00 CST 2018, time=2018-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042081, encodeId=d4cb104208187, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Dec 02 13:42:00 CST 2018, time=2018-12-02, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1931705, encodeId=96371931e055a, content=<a href='/topic/show?id=1a76e6753b9' target=_blank style='color:#2F92EE;'>#糖尿病管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76753, encryptionId=1a76e6753b9, topicName=糖尿病管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7ca4300, createdName=wodejia-dayu, createdTime=Thu Apr 04 06:42:00 CST 2019, time=2019-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377627, encodeId=dd9a13e7627c1, content=<a href='/topic/show?id=5dfe4420fc' target=_blank style='color:#2F92EE;'>#CDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4420, encryptionId=5dfe4420fc, topicName=CDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec25412, createdName=yangpeizhi, createdTime=Tue Dec 04 01:42:00 CST 2018, time=2018-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530486, encodeId=7c031530486ca, content=<a href='/topic/show?id=8309e5153aa' target=_blank style='color:#2F92EE;'>#移动医疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75153, encryptionId=8309e5153aa, topicName=移动医疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fbd812108434, createdName=yahu, createdTime=Tue Dec 04 01:42:00 CST 2018, time=2018-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1625326, encodeId=cb291625326fc, content=<a href='/topic/show?id=604fe6046b2' target=_blank style='color:#2F92EE;'>#管理模式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76046, encryptionId=604fe6046b2, topicName=管理模式)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8adf20737369, createdName=zhangj7115, createdTime=Tue Dec 04 01:42:00 CST 2018, time=2018-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042081, encodeId=d4cb104208187, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Dec 02 13:42:00 CST 2018, time=2018-12-02, status=1, ipAttribution=)]
    2018-12-02 misszhang

    谢谢MedSci提供最新的资讯

    0

相关资讯

JCEM:体重波动与糖尿病、心血管疾病和死亡率

由此可见,体重波动与死亡率相关。此外,体重波动对发生糖尿病的影响取决于基线时肥胖状况。

CDS2018:大庆糖尿病预防30年随访研究揭示生活方式干预降低中国成人IGT患者死亡率

作为全球糖尿病预防领域的里程碑式研究,大庆糖尿病预防研究取得了累累硕果。2018年11月30日,在中华医学会糖尿病学分会第二十二次全国学术会议(CDS2018)的“糖尿病流行病学、卫生经济学及转化医学”专题上,中国医学科学院阜外医院巩秋红教授报告了大庆糖尿病预防30年随访研究结果,揭示了生活方式干预可降低中国成人糖耐量异常(IGT)患者的死亡率。

CDS2018:金标准也须与时俱进:看CGM如何超越HbA1c,助力血糖全面管理

2018年11月30日,在中华医学会糖尿病学分会第二十二次全国学术会议(CDS2018)上,上海交通大学附属第六人民医院包玉倩教授从血糖管理指标方面分析了持续葡萄糖监测(CGM)相较于糖化血红蛋白(HbA1c)用于血糖控制与评估的优势,为广大参会者更深入了解CGM提供了重要信息。

CDS2018:白蛋白尿的重新认识:另一种心肾风险因素?老外专家带您了解一下

糖尿病患者更容易患上肾脏并发症,目前对于糖尿病肾病管理的意识越来越强烈。越来越多的研究打破了原来对白蛋白尿的认识,对于糖尿病肾病管理起到一定的启示作用。

CDS2018:糖尿病肾脏病诊治的新靶点——肾小管上皮细胞

糖尿病所致的肾损害并不仅仅局限于肾小球,肾小管上皮细胞在糖尿病肾脏病(DKD)的早期和进展期均发挥了关键作用。2018年11月30日,在中华医学会糖尿病学分会第二十二次全国学术会议(CDS2018)上,南方医科大学南方医院薛耀明教授从DKD防治的严峻形势入手,介绍了肾小管上皮细胞在DKD发病中的重要性以及肾小管上皮细胞作为DKD治疗新靶点的最新研究进展。

CDS2018:吸粉无数的卡格列净,到底有何过人之处?

随着循证医学证据的积累,糖尿病治疗已经历了从单纯控制高血糖到多因素管理的转变。但是,糖尿病合并心血管疾病(CVD)及肾脏疾病的防控形势依然十分严峻。在中华医学会糖尿病学分会第二十二次全国学术会议(CDS2018)上,由中国人民解放军总医院母义明教授担任主席,中山大学孙逸仙纪念医院李焱教授和天津医科大学代谢病医院陈莉明教授担任讲者,分别从新型降糖药SGLT2抑制剂卡格列净的机制、循证出发,对2型糖尿